Transradial approach for the endovascular treatment of type I endoleak after aortic aneurysm repair: a case report

Gabriele Giacomo Schiattarella1, Fabio Magliulo1, Flora Ilaria Laurino1, Roberta Bottino1, Antonio Giulio Bruno1, Michele De Paulis1, Antonio Sorropago1, Cinzia Perrino1, Bruno Amato2, Dario Leosco3, Bruno Trimarco1, Giovanni Esposito1*

From 26th National Congress of the Italian Society of Geriatric Surgery
Naples, Italy. 19-22 June 2013

Abstract

Background: Endovascular repair of aortic aneurysms (EVAR) is obtained through the positioning of an aortic stent-graft, which excludes the aneurysmatic dilation. Type I endoleak is the most common complication, and it is caused by an incompetent proximal or distal attachment site, causing the separation between the stent-graft and the native arterial wall, and in turn creating direct communication between the aneurysm sac and the systemic arterial circulation. Endoleak occurrence is associated with high intrasac pressures, and requires a quick repair to prevent abdominal aortic aneurysm rupture.

Case presentation: We report the first case of a 80-year-old man undergoing percutaneous closure of a peri-graft endoleak (type I) by transcatheter embolization through radial arterial access.

Conclusion: The transradial approach has been shown to be a safe and effective alternative to the traditional transfemoral approach. A decrease in vascular complications and improved patient comfort are the primary benefits of this technique in patients with previous EVAR.

Background

Peripheral arterial disease (PAD) is one of the most frequent manifestations of atherosclerosis and it is associated to a high incidence of major cardiovascular events [1-5]; it might involve the abdominal aorta, the epi-aortic trunks and the limb arteries [6-8]. Aortic abdominal aneurysms (AAA) are frequent expressions of PAD [9] and represent a frequent cause of mortality and morbidity, particularly in men older than 60 years. AAA particularly affect the iuxtarenal portion of the abdominal aorta and are defined as an increase of the anteroposterior diameter of the aorta of more than 3 cm [10]. Risk factors for developing an AAA are the same of atherosclerosis, in particular the relative risk seems to significantly increase with the number of daily smoked cigarettes [11]. AAA are associated with a high risk of rupture, which is frequently fatal [2,12], so it is necessary to perform preventive measures to avoid such eventuality. Most recent guidelines suggest a threshold of 5.5 cm as anteroposterior aortic diameter to decide for clinical surveillance (when inferior) or for operative measures (when superior), even though AAA with a diameter of 5 cm may be considered for intervention in particular cases [2,13].

The classical intervention for treating an AAA is the surgical excision of the dilated sac and the use of a prosthesis, generally made in Goretex, to restore the vascular continuity; however, despite the improving in surgical and anesthetic techniques, this complex procedure still carries an high peri-operative risk [14,15]. Recently, endovascular aortic repair (EVAR) has been proposed as an attractive alternative for selected patients.

* Correspondence: espogiov@unina.it
1Department of Advanced Biomedical Sciences, Federico II University, via Pansini 5, 80131 Naples, Italy
Full list of author information is available at the end of the article

© 2013 Schiattarella et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
since 1991, when Parodi et al performed the first endovascular positioning of an aortic endoprosthesis excluding the aneurysmatic dilation [16]. Although EVAR short and mid-term results indicate that this procedure is effective and might be even safer than classical open repair, given to the lack of long term follow up data, it is still considered a second choice compared to classic surgery, rather than an equal alternative [2]. Undoubtedly, EVAR downsides include anatomic limitations making this procedure unsuitable in some cases (renal arteries interested into aneurysm sac; short, angulated AAA etc), thrombotic graft occlusions and stent migrations that might cause a re-enlargement of the previously excluded aneurysm [12].

The most frequent complications of EVAR are intrasac endoleaks, which may be defined as the presence of a continuous blood flow into the excluded sac [17]. Currently, the most commonly accepted classification for endoleaks encompasses five types, on the basis of the origin of the anomalous flow (Table 1). Type I endoleaks occur at either a proximal (type IA) or distal (type IB) incompetent attachment site, and allow a persistent communication between the pressure-filled aortic lumen and the aneurysm sac or excluded portion of the aortic lumen, producing high intrasac pressures that can lead to rupture. Type II endoleaks are the result of retrograde flow from branch vessels (for example, lumbar arteries and the inferior mesenteric artery). Type III endoleaks are due to a junctional leak between two modular segments of stent-grafts or due to a graft fabric disruption. As type I endoleaks, they are associated with measureable increases in aneurysm sac size and require urgent management. Type IV endoleaks are the result of high graft porosity and diffuse microleakage through its interstices, usually within 30 days of implantation, and are rare compared with the frequency of other endoleaks. Finally, the terms “type V endoleaks” and “endotension” have been coined to those circumstances in which the excluded sac continues to enlarge despite the absence of any visible endoleaks on contrast-enhanced computed tomographic scans.

The management of post-operative endoleaks depend on the specific type, and in most cases only type I/III require a rapid repair to prevent aneurysm rupture [12,17]. Standard endovascular treatment options for type IA endoleaks include the insertion of an aortic cuff to extend endograft coverage more proximally, or the placement of a large-caliber balloon-expandable stent (e.g. Palmaz or Sinus) inside the proximal endograft to promote the seal. Standard therapy for type IB endoleaks involves distal extension of endograft coverage. If an endoleak persists despite these measures, definitive therapy may require conventional open surgery, combining visceral artery bypass with stent-graft extension or the use of chimney or periscope grafts to extend proximal and distal landing zones.

Patients who are not eligible for these more complex procedures, because of severe co-morbidities or adverse anatomical factors, may be treated by trans-catheter embolization of the endoleak itself. There is limited published experience of type I endoleak embolization and previous reports have involved coils and n-butyl 2-cyanoacrylate (n-BCA). Onyx (ev3, Irvine, CA, USA) is a relatively novel non-adhesive liquid embolic agent, which is most commonly used to treat intracranial arteriovenous malformations. It is comprised of ethylene vinyl alcohol dissolved in dimethyl sulphoxide (DMSO), an organosulfur compound frequently employed into molecular biology studies [18,19], and suspended micronized tantalum powder to provide contrast for visualization under fluoroscopy [20].

Treatment of EVAR endoleaks is generally performed through femoral arterial access; however, radial access are generally associated to lower costs, fewer vascular complications and earlier ambulation. We describe a first case of a patient undergoing percutaneous closure of a type I peri-graft endoleak by embolization release controlled spirals and liquid embolization Onyx through radial arterial access.

**Case presentation**

An 80-year-old man, affected by coronary artery disease, chronic obstructive pulmonary disease, arterial hypertension and dyslipidemia, former heavy smoker, was admitted to our Department on May 5, 2011. Previous Doppler ultrasound exams had shown the presence of an aneurysmatic dilatation of the infra-renal portion of the aorta, which had been followed-up until reaching a maximum diameter of almost 5.2 cm (January 2011). Thus, the patient underwent computed tomography (CT) angiographic imaging, which demonstrated aneurysm sac shrinkage of about 5 x 5.5 cm, with a longitudinal extension of about 8 cm and showed also signs of

---

**Table 1 Endoleaks classification**

| Type | Description |
|------|-------------|
| IIA  | Proximal end of endograft |
| IIB  | Distal end of endograft |
| IC   | Iliac occluder (plug) |
| IIA  | From only 1 patent branch |
| IIB  | From 2 or more patent branches |
| IIIA | Junctional leak or modular disconnect |
| IIIIB| Fabric disruption (midgraft hole) |
| Type IV | Graft wall (fabric) porosity (<30 d after graft placement) |
| Type V | Aneurysm sac enlargement with no detectable endoleak |
mural thrombotic apposition of about 3 cm of maximum axial thickness.

Physical examination evidenced a tender and pulsatile abdominal mass, accompanied by the auscultatory finding of a systolic murmur in the paraumbilical region. During the hospitalization, aortic ecotomography was repeated and revealed maximum diameters of the aneurysmatic formation of about 6 × 5.8 cm, confirming the presence of a large, eccentric intra-sac thrombus. The patient also underwent coronary angiography, which showed significant stenosis of the left anterior descending coronary artery and of the circumflex coronary artery, which were judged not amenable of percutaneous treatment. Given the size of the aneurysm sac (and, in particular, the progressive and quick enlargement), the presence of intramural thrombotic burden causing a not trivial potential risk of a severe peripheral embolism and the severe coronary artery disease, we decided to perform EVAR with implantation of an aorto-bisiliac endoprosthesis, using surgical isolation and access of the left common femoral artery and percutaneous access of the right common femoral artery. At the final angiographic control, no endoleak was visible. The following hospital course was completely devoid of complications, without significant post-operative anemia or signs of infections, and the patient was discharged five days after the procedure.

In July 2012, a routine CT control revealed the presence of an apparent type I endoleak. The patient was in a clinically stable state (without any symptoms and no signs of anemia). Aortography confirmed the presence of a posterior peri-graft large leak (Figure 1A). The patient declined the high-risk option of open surgical repair in favor of a final endovascular attempt. He underwent percutaneous closure of the peri-graft endoleak (type I) by means of embolization release controlled spirals and liquid embolization Onyx. Transarterial embolization was performed via the radial artery approach. A right radial access was obtained using a micro-puncture kit (Cook Medical), and a 6 Fr sheath (Cordis) was placed in the right radial artery without difficulty. The endoleak channel was engaged with a (SOS Omni) selective catheter. The presence and location of the type I endoleak was confirmed by aortography. The aneurysm sac was treated using embolization release controlled spirals and liquid embolization Onyx (Micro Therapeutics Iac, Irvine, Calif) (Figure 1B). Before injection of Onyx, the microcather was flushed with DMSO and Onyx was subsequently injected under fluoroscopy. We used the currently available solutions Onyx-18 (6 % Ethylene vinyl alcohol (EVOH)/94 % DMSO), Onyx-20 (6.5 % EVOH/93.5 % DMSO) or Onyx-34 (8 % EVOH/92 % DMSO). Onyx-18 had the lowest and Onyx-34 the highest viscosity. Post-embolization angiography showed no further endoleak (Figure 1C). At 3-month-follow-up, the patient was free of radiographic evidence of type I endoleak or aneurysm sac expansion.

Conclusions
Endovascular treatment of aortic aneurysms has progressively improved and has widely replaced the classical surgical procedures [6-8,21-24]. EVAR is widely

Figure 1. A. Angiogram following placement of aortic endograft shows a type I endoleak. B. Closure of perigraft endoleak by means of embolization release controlled spirals and liquid embolization Onyx. C. Angiogram showing resolution of Type I endoleak.
accepted as a safer and less invasive alternative to open repair. The most common complication of EVAR is endoleak, which occurs when the aortic sac continues to be perfused despite graft fixation. Type I endoleaks are the most frequent and occur at either proximal or distal attachment site or landing zone. These leaks are consequence of a failing apposition of the stent-graft to the cylindrical aortic wall within the landing zone allowing a persistent communication between the pressure-filled aortic lumen and the aneurysm sac or excluded portion of the aortic lumen. The EUROSTAR investigators have also demonstrated that endoleak type I is significantly associated with rupture risk after EVAR [25]. Endovascular technique has significantly decreased mortality rate when compared to open surgery. Endovascular treatment of type I endoleaks requires a complete flow elimination to exclude the aneurysm sac from systemic pressure.

The transradial approach appears to be a safe and effective alternative to the traditional transfemoral approach. The primay benefits of this technique, when compared to femoral artery access, are a decrease in vascular complications, improved patient comfort, earlier ambulation and lower direct costs. Asymptomatic radial artery occlusion, non-occlusive radial artery injury and radial artery spasm are commonly reported complications [26,27]. Symptomatic radial artery occlusion, pseudoaneurysm and radial artery perforation are much less common. The risk of arterial perforation with the transradial approach is less than 1%, primarily involving the radial artery with the incidence of compartment syndrome at approximately 0.004% [28]. In addition, the risk of significant bleeding requiring transfusion with the transradial approach is extremely rare, occurring in about one patient in a thousand [29].

In this report, we present a case of successful endovascular treatment of type I endoleak by embolization release controlled spirals and liquid embolization Onyx. For trans-arterial embolization, many authors reported the use of microcoils or n-BCA as embolizing materials, but Onyx has shown safety advantages [30]. Onyx is an ethylene vinyl alcohol copolymer dissolved in various concentrations of DMSO and opacified with micronized Tantalum powder for X-ray visualization. When this mixture contacts blood, DMSO diffuses away resulting in solidification of the polymer [31]. Disadvantages of the use of Onyx for endoleak treatment are its high radio-opacity on follow-up CT scans (causing a difficult detection of small persistent endoleaks, comparable to artifacts with coils after endoleak embolization and image subtraction), a relatively long (20 minutes) preparation time, the potential for vasospasm and the high costs [32,33]. Embolization is considered clinically successful when the volume of the aneurysm sac is stable or decreased at follow-up CT scans.

In conclusion, endoleaks remain the primary limitation of endovascular stent-grafting of the abdominal aorta. Type I endoleak is associated with a significantly greater risk of rupture of the aneurysm. Many patients will be able to benefit from endovascular treatment approach to aortic disease through radial arterial access. Larger patient numbers and longer-term follow-up are needed to define procedural efficacy and durability.

**Consent**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of written consent is available for review by the Editor-in-Chief of this journal.

**Abbreviations**

EVAR: Endovascular repair of aortic aneurysms; PAD: Peripheral arterial disease; AAA: Aortic abdominal aneurysms; DMSO: Dimethyl Sulphoxide; n-BCA: n-butyl 2-cyanoacrylate

**Competing interests**

Authors declare that they have no competing interests. No financial support has been received.

**Authors’ contributions**

GGS, GE and CP acquired the data and wrote/revised the manuscript. FM, FIL, AGB, MDP, AS performed the clinical follow-up of the patient. GE and GGS performed the endovascular treatment. BT and GE approve the final manuscript. Furthermore, all authors have been involved in reviewing the manuscript critically for important intellectual content and read and approved the final manuscript.

**Authors’ information**

GGS: Resident in Cardiology at University Federico II of Naples. FM: Resident in Cardiology at University Federico II of Naples. FIL: Resident in Cardiology at University Federico II of Naples. RB: Resident in Cardiology at University Federico II of Naples. AGB: Resident in Cardiology at University Federico II of Naples. MDP: Resident in Cardiology at University Federico II of Naples. AS: Resident in Cardiology at University Federico II of Naples. CP: Assistant Professor of Internal Medicine at University Federico II of Naples. BA: Associate Professor of Surgery at University “Federico II” of Naples. DL: Associate Professor of Internal Medicine and Geriatrics at University “Federico II” of Naples.

BT: Full Professor of Cardiology at University Federico II of Naples, Chief Division of Cardiology at University Federico II of Naples. GE: Associate Professor of Cardiology at University “Federico II” of Naples.

**Declarations**

Funding for this article came from personal funds. This article has been published as part of BMC Surgery Volume 13 Supplement 2, 2013: Proceedings from the 26th National Congress of the Italian Society of Geriatric Surgery. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcsurg/supplements/13/S2

**Authors’ details**

1Department of Advanced Biomedical Sciences, Federico II University, via Pansini 5, 80131 Naples, Italy. 2Department of Clinical Medicine and Surgery, Federico II University, via Pansini 5, 80131 Naples, Italy. 3Department of Translational Medical Sciences, Federico II University, via Pansini 5, 80131 Naples, Italy.

Published: 8 October 2013
